Previous close | 4.8500 |
Open | 4.8400 |
Bid | 4.7400 x 200 |
Ask | 4.7900 x 200 |
Day's range | 4.7600 - 4.9450 |
52-week range | 3.5300 - 11.3600 |
Volume | |
Avg. volume | 8,628,157 |
Market cap | 668.975M |
Beta (5Y monthly) | 1.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.4100 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.40 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Novavax, Inc. ( NASDAQ:NVAX ) missed earnings with its latest full-year results, disappointing overly-optimistic...
Novavax ( NASDAQ:NVAX ) Full Year 2023 Results Key Financial Results Revenue: US$983.7m (down 50% from FY 2022). Net...